Chronic Rhinosinusitis, Nasal Polyps
Conditions
Brief summary
The purpose of this study is to determine the efficacy and safety of omalizumab compared with placebo in adult participants with chronic rhinosinusitis with nasal polyps (CRSwNP) who have had an inadequate response to standard-of-care treatments. Study GA39855 (POLYP 2; NCT03280537) was another Phase III study by the Sponsor with identical objectives and design and was run in parallel with this study.
Interventions
DRUGOmalizumab
Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table.
DRUGPlacebo
Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table.
Sponsors
Hoffmann-La Roche
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Age 18-75 years, inclusive, at time of signing Informed Consent Form. * Ability to comply with the study protocol, in the investigator's judgment. * Nasal polyp score (NPS) \>= 5, with a unilateral score of \>= 2 for each nostril, at screening (Day -35), and on Day -7. * Sino-Nasal Outcome Test-22 (SNOT-22) score \>=20 at screening (Day -35) and at randomization (Day 1). * Treatment with at least nasal mometasone 200 micro gram per day, or equivalent daily dosing of nasal corticosteroid (CS), for at least 4 weeks before screening (Day -35). * Treatment with nasal mometasone 200 micro gram twice a day (BID) (or once a day \[QD\] if intolerant to twice daily) during the run-in period with an adherence rate of at least 70%. * Presence of nasal blockage/congestion with NCS \>=2 (1-week recall) at Day -35 and an average of the daily NCS score over the 7 days prior to randomization of NCS \>1 with at least one of the following symptoms prior to screening: nasal discharge (anterior/posterior nasal drip) and/or reduction or loss of smell. * Eligibility per the study drug dosing table * Willingness to maintain all background medications stable for the duration of the treatment and follow-up periods. * Willingness and ability to use electronic device to enter study-related information in electronic devices (electronic diary \[eDiary\]/electronic tablet \[eTablet\]). * Demonstration of at least 70% adherence to eDiary daily symptom assessment during run in period, with fully completed entries on at least 4 days in the week prior to randomization. * For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use acceptable contraceptive methods during the treatment period and for 60 days after the last dose of study drug.
Exclusion criteria
* Known history of anaphylaxis/hypersensitivity to omalizumab. * Treatment with investigational drugs within 12 weeks or 5 half-lives (whichever is longer) prior to screening (Day -35). * Treatment with monoclonal antibodies (e.g., omalizumab, mepolizumab) for 6 months prior to screening (Day -35). * Current treatment with leukotriene antagonists/modifiers, unless participant has been on stable dosing of such medication for at least 1 month prior to screening (Day -35). * Treatment with non-steroid immunosuppressants within 2 months or 5 half-lives, whichever is longer, prior to screening (Day -35). * Treatment with systemic corticosteroids, except when used as treatment for nasal polyposis, within 2 months prior to screening (Day -35). * Usage of systemic CS during the run-in period. Participants requiring systemic CS during run-in may be rescreened after completing systemic CS. * Treatment with intranasal CS drops or CS administering devices (e.g., OptiNose device or stents) within 1 month prior to screening (Day -35) or during the run-in period. * History of nasal surgery (including polypectomy) within 6 months prior to screening. * History of sinus or nasal surgery modifying the structure of the nose such that assessment of NPS is not possible. * Uncontrolled epistaxis requiring surgical or procedural intervention, including nasal packing, within 2 months prior to screening. * Known or suspected diagnosis of cystic fibrosis, primary ciliary dyskinesia (e.g., Kartagener syndrome) or other dyskinetic ciliary syndromes, hypogammaglobulinemia or other immune deficiency syndrome, chronic granulomatous disease and granulomatous vasculitis, granulomatosis with polyangiitis (e.g., Wegener's Granulomatosis), or eosinophilic granulomatous with polyangiitis (EGPA) (e.g., Churg-Strauss syndrome). * Presence of antrochoanal polyps. * Concomitant conditions that interfere with evaluation of primary endpoint: * Nasal septal deviation occluding one or both nostrils. * Ongoing rhinitis medicamentosa. * Acute sinusitis, nasal infection, or upper respiratory infection during the run-in period. * Known or suspected invasive or expansive fungal rhinosinusitis. * Known HIV infection at screening. * Known acute and chronic infections with hepatitis C virus (HCV) and hepatitis B virus (HBV) at screening. * History of myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack or a known history of a hypercoagulable disorder. * Active tuberculosis requiring treatment within 12 months prior to screening (Day -35). * Initiation of or change in allergen immunotherapy within 3 months prior to screening (Day -35) or during the run-in period. * Initiation of or change in aspirin desensitization within 4 months prior to screening (Day -35) or during the run-in period. * Pregnant or breastfeeding, or intending to become pregnant during the study or within 60 days after the last dose of omalizumab. * Current malignancy or history of malignancy within 5 years prior to screening, except for appropriately treated carcinoma in situ of the cervix or non-melanoma skin carcinoma that has been treated or excised and is considered resolved. * Any serious medical condition (including but not limited to significant arrhythmia, uncontrolled hypertension, significant pulmonary disease other than asthma) or abnormality in clinical laboratory tests that precludes the participant's safe participation in and completion of the study. * History of alcohol, drug, or chemical abuse within 6 months of screening.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Nasal Polyp Score (NPS) at Week 24 | Baseline, Week 24 | Total NPS ranges from 0 to 8 (sum of 0-4 for left and right nasal passage scores per the following criteria), with a lower score indicating smaller-sized nasal polyps: 0 = No polyps; 1 = Small polyps in the middle meatus not reaching below the inferior border of the middle turbinate; 2 = Polyps reaching below the lower border of the middle turbinate (modified to accommodate those with a middle turbinectomy, such that polyp must have reached the top of the inferior turbinate.); 3 = Large polyps reaching the lower border of the inferior turbinate or polyps medial to the middle turbinate; and 4 = Large polyps causing complete obstruction of the inferior nasal cavity. Two blinded primary independent expert readers reviewed every post-screening recorded video endoscopy for a given participant to determine total NPS. A third reader chose one of the two scores to be used for analysis in cases where there was any discrepancy in total NPS assigned between the two primary readers. |
| Change From Baseline in Average Daily Nasal Congestion Score (NCS) at Week 24 | Baseline, Week 24 (Study Days 155 to 186) | The Nasal Congestion Score (NCS) was assessed daily by the participant via an electronic diary as the response to the following question: Is your nose blocked? The four available response options were scored from 0 (no symptoms) to 3 (severe symptoms): 0 = Not at all; 1 = Mild; 2 = Moderate; and 3 = Severe. For each study day, a score was calculated using an average of the prior 7 days among the available days within the pre-specified window (For Week 24: Study Days 155 to 186), excluding the study day itself, if a value had been recorded by the participant on at least 4 of the prior 7 days; otherwise, the 7-day prior average for that study day was to be considered missing. One calculated (non-missing) 7-day prior average was selected for analysis according to the study day with nearest proximity to Week 24 (Study Day 168), with the earlier selected in the case of a tie. Baseline was defined as the (non-missing) 7-day interval ending on the latest day prior to randomization. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Nasal Polyp Score (NPS) at Week 16 | Baseline, Week 16 | Total NPS ranges from 0 to 8 (sum of 0-4 for left and right nasal passage scores per the following criteria), with a lower score indicating smaller-sized nasal polyps: 0 = No polyps; 1 = Small polyps in the middle meatus not reaching below the inferior border of the middle turbinate; 2 = Polyps reaching below the lower border of the middle turbinate (modified to accommodate those with a middle turbinectomy, such that polyp must have reached the top of the inferior turbinate.); 3 = Large polyps reaching the lower border of the inferior turbinate or polyps medial to the middle turbinate; and 4 = Large polyps causing complete obstruction of the inferior nasal cavity. Two blinded primary independent expert readers reviewed every post-screening recorded video endoscopy for a given participant to determine total NPS. A third reader chose one of the two scores to be used for analysis in cases where there was any discrepancy in total NPS assigned between the two primary readers. |
| Change From Baseline in Average Daily Nasal Congestion Score (NCS) at Week 16 | Baseline, Week 16 (Study Days 99 to 126) | The Nasal Congestion Score (NCS) was assessed daily by the participant via an electronic diary as the response to the following question: Is your nose blocked? The four available response options, scored from 0 (no symptoms) to 3 (severe symptoms) were: 0 = Not at all; 1 = Mild; 2 = Moderate; and 3 = Severe. For each study day, a score was calculated using an average of the prior 7 days among the available days within the pre-specified window (For Week 16: Study Days 99 to 126), excluding the study day itself, if a value had been recorded by the participant on at least 4 of the prior 7 days; otherwise, the 7-day prior average for that study day was to be considered missing. One calculated (non-missing) 7-day prior average was selected for analysis according to the study day with nearest proximity to Week 24 (Study Day 112), with the earlier selected in the case of a tie. Baseline was defined as the (non-missing) 7-day interval ending on the latest day prior to randomization. |
| Change From Baseline in Participant Reported Health-Related Quality of Life (HRQoL) as Assessed by the Total Sino-Nasal Outcome Test (SNOT)-22 Questionnaire at Week 24 | Baseline, Week 24 | The SNOT-22 Questionnaire, a disease specific HRQoL measure, comprises a list of 22 symptoms and social or emotional consequences of the nasal disorder. Every participant was asked to rate how severe each problem had been for them over the past 2 weeks on a scale from 0 (no problem at all) to 5 (problem as bad as it can be). The total score is the sum of the scores for all 22 items, ranging from 0 to 110, with a lower score indicating less disease and better HRQoL. A negative score indicates a decrease (or improvement) from the baseline score. |
| Change From Baseline in Average Daily Anterior Rhinorrhea Score at Week 24 | Baseline, Week 24 (Study Days 155 to 186) | The Anterior Rhinorrhea Score was assessed daily by the participant via an electronic diary as the response to the following question: Do you have a runny nose? The four available response options were scored from 0 (no symptoms) to 3 (severe symptoms): 0=Not at all; 1=Mild; 2=Moderate; and 3=Severe. For each study day, a score was calculated using an average of the prior 7 days among available days within a pre-specified window (For Week 24: Study Days 155 to 186), excluding the study day itself, if a value had been recorded by the participant on at least 4 of the prior 7 days, otherwise the 7-day prior average for that study day was to be considered missing. One calculated (non-missing) 7-day prior average was selected for analysis according to the study day with nearest proximity to Week 24 (Study Day 168), with the earlier selected in the case of a tie. Baseline was defined as the (non-missing) 7-day interval ending on the latest day prior to randomization. |
| Number of Participants Requiring Rescue Medication (Systemic Corticosteroids for ≥3 Consecutive Days) Through Week 24 | Up to Week 24 | A participant was considered to have had the event of requiring rescue medication if they had taken systemic corticosteroids for 3 or more consecutive days at any point between randomization and Week 24; if the participant had greater than 155 days of follow-up on study and had not taken systemic corticosteroids for 3 or more consecutive days, then they did not have the event. Participants with less than 155 days of follow-up on the study were classified as having had the event if they discontinued study drug due to adverse event, progressive disease, or lack of efficacy and remained missing; if the participant had less than 155 days of follow-up on study and had not already met these criteria, they were classified as having a missing outcome. The null hypothesis was to be assessed by the Wald Chi-square test of the treatment term in the logistic regression model. If model convergence was an issue, then Fisher's Exact test was to be used. |
| Number of Participants Having Had Surgery for Nasal Polyps Through Week 24 | Up to Week 24 | A participant was considered to have had the event of surgery for nasal polyps if they underwent the procedure at any point between randomization and Week 24; if the participant had greater than 155 days of follow-up on study and had not undergone surgery for nasal polyps, then they did not have the event. Participants with less than 155 days of follow-up on the study were classified as having had the event if they discontinued study drug due to adverse event, progressive disease, or lack of efficacy and remained missing; if the participant had less than 155 days of follow-up on study and had not already met these criteria, they were classified as having a missing outcome. The null hypothesis was to be assessed by the Wald Chi-square test of the treatment term in the logistic regression model. If model convergence was an issue, then Fisher's Exact test was to be used. |
| Number of Participants With a Change From Baseline at Week 24 in Asthma Quality of Life Questionnaire (AQLQ) of ≥0.5 in Participants With Comorbid Asthma Only | Baseline, Week 24 | The AQLQ is a 32-item participant-reported measure of asthma-related quality of life (QoL) with a total score (the mean of all 32 responses) ranging from 1 (severely impaired) to 7 (not impaired at all); a higher score indicates a better QoL. An increase of at least 0.5 points in the AQLQ score was considered the minimal important difference for improvement in QoL. |
| Number of Participants Requiring Rescue Treatment (Systemic Corticosteroids For ≥3 Consecutive Days or Having Had Surgery for Nasal Polyps) Through Week 24 | Up to Week 24 | A participant was considered to have had the event of requiring rescue treatment if they had taken systemic corticosteroids for 3 or more consecutive days or had nasal polypectomy at any point between randomization and Week 24; if the participant had greater than 155 days of follow-up on study and had not received rescue treatment, then they did not have the event. Participants with less than 155 days of follow-up on the study were classified as having had the event if they discontinued study drug due to adverse event, progressive disease, or lack of efficacy and remained missing; if the participant had less than 155 days of follow-up on study and had not already met these criteria, they were classified as having a missing outcome. The null hypothesis was to be assessed by the Wald Chi-square test of the treatment term in the logistic regression model. If model convergence was an issue, then Fisher's Exact test was to be used. |
| Number of Participants With Reduction in the Need for Surgery for Nasal Polyps by Week 24, as Defined by an NPS of ≤4 (Unilateral Score of ≤2 on Each Side) and Improvement in SNOT-22 Score of ≥8.9 | Up to Week 24 | A participant was considered to have had the event of reduction in the need for surgery for nasal polyps if they had a Nasal Polyp Score (NPS) of ≤4 and an improvement in the SNOT-22 score of ≥8.9 (minimal important difference) without rescue treatment at Week 24; if the participant had received rescue treatment or had discontinued study drug due to adverse event, progressive disease, or lack of efficacy and remained missing, then they did not have the event. Participants without an intercurrent event and without valid Week 24 assessments of both NPS and SNOT-22 were classified as having a missing outcome. The null hypothesis was to be assessed by the Wald Chi-square test of the treatment term in the logistic regression model. If model convergence was an issue, then Fisher's Exact test was to be used. |
| Change From Baseline in Average Daily Sense of Smell Score at Week 24 | Baseline, Week 24 (Study Days 155 to 186) | The Sense of Smell Score was assessed daily by the participant via an electronic diary as the response to the following question: Is your sense of smell reduced? The four available response options were scored from 0 (no symptoms) to 3 (severe symptoms): 0 = Not at all; 1 = Mild; 2 = Moderate; and 3 = Severe. For each study day, a score was calculated using an average of the prior 7 days among the available days within the pre-specified window (For Week 24: Study Days 155 to 186), excluding the study day itself, if a value had been recorded by the participant on at least 4 of the prior 7 days; otherwise, the 7-day prior average for that study day was to be considered missing. One calculated (non-missing) 7-day prior average was selected for analysis according to the study day with nearest proximity to Week 24 (Study Day 168), with the earlier selected in the case of a tie. Baseline was defined as the (non-missing) 7-day interval ending on the latest day prior to randomization. |
| Change From Baseline in Sense of Smell, as Assessed by The University of Pennsylvania Smell Identification Test (UPSIT) at Week 24 | Baseline, Week 24 | The UPSIT is a 40-question instrument that measures an individual's ability to detect odors and ranges from 0 to 40, with a higher score indicating a better sense of smell. It is a self-administered scratch-and-sniff test provided in booklets that have 40 microencapsulated odorants, each with a multiple-choice option for the response. The number of correct responses is summed to provide a total score. |
| Number of Participants Who Experienced at Least One Adverse Event by Greatest Severity | Up to Week 28 | All adverse events (AE) were treatment emergent AEs, defined as any new AE or any worsening of an existing condition with an onset date on or after the first study drug administration date. AEs were assessed for severity according to the following grading scale: mild (discomfort noticed, but no disruption of normal daily activity), moderate (discomfort sufficient to reduce or affect normal daily activity), or severe (incapacitating with inability to work or to perform normal daily activity). The terms severe and serious are not synonymous; regardless of severity, some events may have also met seriousness criteria. Multiple occurrences of the same AE in one individual are counted once at the greatest intensity. |
| Number of Participants Who Experienced at Least One Serious Adverse Event | Up to Week 28 | A serious adverse event was defined as any adverse event that met any of the following criteria: was fatal; was life-threatening; required or prolonged inpatient hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the study drug; or, was a significant medical event in the investigator's judgment. Multiple occurrences of the same serious adverse event in one individual were counted once. |
| Number of Participants With Adverse Events Leading to Omalizumab/Placebo Discontinuation | Up to Week 24 | — |
| Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Up to Week 28 | Clinical laboratory tests for serum chemistry and hematology parameters were performed at laboratories; any abnormal values (High or Low) were based on laboratory normal ranges. Laboratory abnormalities are presented by the highest grade according to the World Health Organization (WHO) grade for Adverse Events, except for eosinophils and white blood cells that were graded according to the FDA Toxicity Grading Scale for Healthy Volunteers. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. SGPT/ALT = serum glutamic-pyruvic transaminase/alanine aminotransferase; SGOT/AST = serum glutamic-oxaloacetic transaminase/aspartate aminotransferase |
| Mean Serum Concentration of Omalizumab at Specified Timepoints | Predose on Day 1, Week 16, Week 24, Unscheduled Visit (outside of planned study visits, as clinically indicated), Dosing Termination/Early Termination Visit (up to 28 weeks) | Serum concentrations of omalizumab were quantified using an enzyme-linked immunoabsorbent assay (ELISA) with a lower limit of quantification (LLOQ) of 28.0 nanograms per millilitre (ng/mL). According to the analysis plan, values below the lower limit of quantification (BLQ) were set to 14 ng/mL (i.e. half of LLOQ value). If one-third or fewer of participants had results that were BLQ, then all summary statistics were to be calculated. However, if more than one-third of participants had results that were BLQ, then the mean and standard deviation were non-reportable and only the median and maximum were to be calculated for that timepoint. |
| Median Serum Concentration of Omalizumab at Specified Timepoints | Predose on Day 1, Week 16, Week 24, Unscheduled Visit (outside of planned study visits, as clinically indicated), Dosing Termination/Early Termination Visit (up to 28 weeks) | Serum concentrations of omalizumab were quantified using an enzyme-linked immunoabsorbent assay (ELISA) with a lower limit of quantification (LLOQ) of 28.0 nanograms per millilitre (ng/mL). According to the analysis plan, values below the lower limit of quantification (BLQ) were set to 14 ng/mL (i.e. half of LLOQ value). If one-third or fewer of participants had results that were BLQ, then all summary statistics were to be calculated. However, if more than one-third of participants had results that were BLQ, then the mean and standard deviation were non-reportable and only the median and maximum were to be calculated for that timepoint. |
| Mean Serum Concentration of Total and Free Immunoglobulin E (IgE) at Specified Timepoints | Predose on Day 1, Week 16, Week 24 | Serum concentrations of total immunoglobulin E (IgE) and free IgE were measured throughout the 24-week blinded treatment period, as target engagement biomarkers of omalizumab, using validated quantitative immunoassays with lower limits of quantification of 2 and 0.83 International Units per millilitre (IU/mL), respectively, and upper limits of quantification (ULQ) of 5000 and 62.5 IU/mL, respectively. The free IgE assay had limited range to measure circulating levels of free IgE in the presence of complexes of omalizumab-IgE. According to the analysis plan for the free IgE assay, results above ULQ were set to 62.5 IU/mL. If results for one-third or fewer of the participants were greater than the ULQ, then all summary statistics were to be reported. However, if the results for more than one-third of participants were greater than the ULQ, then only the median, interquartile range and minimum were calculated, and the mean, standard deviation, and maximum were non-reportable. |
| Median Serum Concentration of Total and Free Immunoglobulin E (IgE) at Specified Timepoints | Predose on Day 1, Week 16, Week 24 | Serum concentrations of total immunoglobulin E (IgE) and free IgE were measured throughout the 24-week blinded treatment period, as target engagement biomarkers of omalizumab, using validated quantitative immunoassays with lower limits of quantification of 2 and 0.83 International Units per millilitre (IU/mL), respectively, and upper limits of quantification (ULQ) of 5000 and 62.5 IU/mL, respectively. The free IgE assay had limited range to measure circulating levels of free IgE in the presence of complexes of omalizumab-IgE. According to the analysis plan for the free IgE assay, results above ULQ were set to 62.5 IU/mL. If results for one-third or fewer of the participants were greater than the ULQ, then all summary statistics were to be reported. However, if the results for more than one-third of participants were greater than the ULQ, then only the median, interquartile range and minimum were calculated, and the mean, standard deviation, and maximum were non-reportable. |
| Change From Baseline in Average Daily Total Nasal Symptom Score (TNSS) at Week 24 | Baseline, Week 24 (Study Days 155 to 186) | The Total Nasal Symptom Score (TNSS) was defined as the sum of the four individual scores for Nasal Congestion Score, Anterior Rhinorrhea Score, Posterior Rhinorrhea Score, and Sense of Smell Score, ranging from 0 (no symptoms) to 12 (most severe symptoms), assessed daily by the participant via an electronic diary. For each study day, a score was calculated using an average of the prior 7 days among the available days within the pre-specified window (For Week 24: Study Days 155 to 186), excluding the study day itself, if a value had been recorded by the participant on at least 4 of the prior 7 days; otherwise, the 7-day prior average for that study day was to be considered missing. One calculated (non-missing) 7-day prior average was selected for analysis according to the study day with nearest proximity to Week 24 (Study Day 168), with the earlier selected in the case of a tie. Baseline was defined as the (non-missing) 7-day interval ending on the latest day prior to randomization. |
| Change From Baseline in Average Daily Posterior Rhinorrhea Score at Week 24 | Baseline, Week 24 (Study Days 155 to 186) | The Posterior Rhinorrhea Score was assessed daily by the participant via an electronic diary as the response to the following question: Do you feel dripping at the back of the nose? The four available response options were scored from 0 (no symptoms) to 3 (severe symptoms): 0=Not at all; 1=Mild; 2=Moderate; and 3=Severe. For each study day, a score was calculated using an average of the prior 7 days among available days within a pre-specified window (For Week 24: Study Days 155 to 186), excluding the study day itself, if a value had been recorded by the participant on at least 4 of the prior 7 days, otherwise the 7-day prior average for that study day was to be considered missing. One calculated (non-missing) 7-day prior average was selected for analysis according to the study day with nearest proximity to Week 24 (Study Day 168), with the earlier selected in the case of a tie. Baseline was defined as the (non-missing) 7-day interval ending on the latest day prior to randomization. |
Countries
Canada, Czechia, Germany, Mexico, Poland, Portugal, Russia, Ukraine, United Kingdom, United States
Participant flow
Pre-assignment details
At the first visit of the 5-week screening/run-in period, participants were asked to standardize their nasal corticosteroids to a regimen of mometasone, 200 micrograms twice a day (BID). If intolerant to a BID regimen, then they remained on a stable dosage of mometasone once a day (QD) during the run-in period and throughout the treatment period.
Participants by arm
| Arm | Count |
|---|---|
| Placebo Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table. All participants were also treated during the entire study with intranasal corticosteroids (mometasone nasal spray) as background therapy. | 66 |
| Omalizumab Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table. All participants were also treated during the entire study with intranasal corticosteroids (mometasone nasal spray) as background therapy. | 72 |
| Total | 138 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Physician Decision | 0 | 1 |
| Overall Study | Withdrawal by Subject | 2 | 2 |
Baseline characteristics
| Characteristic | Omalizumab | Total | Placebo |
|---|---|---|---|
| Age, Continuous | 50.0 years STANDARD_DEVIATION 14.5 | 51.0 years STANDARD_DEVIATION 13.2 | 52.2 years STANDARD_DEVIATION 11.6 |
| Average Daily Anterior Rhinorrhea Score at Baseline | 1.9 Score on a scale STANDARD_DEVIATION 0.8 | 2.0 Score on a scale STANDARD_DEVIATION 0.8 | 2.1 Score on a scale STANDARD_DEVIATION 0.8 |
| Average Daily Nasal Congestion Score at Baseline | 2.4 Score on a scale STANDARD_DEVIATION 0.7 | 2.4 Score on a scale STANDARD_DEVIATION 0.6 | 2.5 Score on a scale STANDARD_DEVIATION 0.6 |
| Average Daily Posterior Rhinorrhea Score at Baseline | 1.7 Score on a scale STANDARD_DEVIATION 0.9 | 1.8 Score on a scale STANDARD_DEVIATION 0.9 | 2.0 Score on a scale STANDARD_DEVIATION 0.9 |
| Average Daily Sense of Smell Score at Baseline | 2.6 Score on a scale STANDARD_DEVIATION 0.8 | 2.7 Score on a scale STANDARD_DEVIATION 0.7 | 2.8 Score on a scale STANDARD_DEVIATION 0.4 |
| Daily Total Nasal Symptom Score (TNSS) at Baseline | 8.6 Score on a scale STANDARD_DEVIATION 2.5 | 8.9 Score on a scale STANDARD_DEVIATION 2.3 | 9.3 Score on a scale STANDARD_DEVIATION 1.9 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 9 Participants | 14 Participants | 5 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 62 Participants | 123 Participants | 61 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants | 1 Participants | 0 Participants |
| Geographic Region of Enrollment ex-North America | 49 Participants | 96 Participants | 47 Participants |
| Geographic Region of Enrollment North America | 23 Participants | 42 Participants | 19 Participants |
| Mometasone Prescribed Daily Dose at Baseline 200 micrograms | 4 Participants | 8 Participants | 4 Participants |
| Mometasone Prescribed Daily Dose at Baseline 400 micrograms | 68 Participants | 130 Participants | 62 Participants |
| Nasal Polyp Score (NPS) at Baseline | 6.2 Score on a scale STANDARD_DEVIATION 1 | 6.2 Score on a scale STANDARD_DEVIATION 1 | 6.3 Score on a scale STANDARD_DEVIATION 0.9 |
| Participants with Asthma Comorbidity and Aspirin Sensitivity Asthmatic and Aspirin Sensitive | 14 Participants | 24 Participants | 10 Participants |
| Participants with Asthma Comorbidity and Aspirin Sensitivity Asthmatic and Not Aspirin Sensitive | 28 Participants | 50 Participants | 22 Participants |
| Participants with Asthma Comorbidity and Aspirin Sensitivity Not Asthmatic | 30 Participants | 64 Participants | 34 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 2 Participants | 2 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants | 2 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 3 Participants | 3 Participants | 0 Participants |
| Race (NIH/OMB) White | 65 Participants | 131 Participants | 66 Participants |
| Sex: Female, Male Female | 25 Participants | 50 Participants | 25 Participants |
| Sex: Female, Male Male | 47 Participants | 88 Participants | 41 Participants |
| Total Sino-Nasal Outcome Test-22 (SNOT-22) Score at Baseline | 59.8 Score on a scale STANDARD_DEVIATION 19.7 | 60.1 Score on a scale STANDARD_DEVIATION 17.7 | 60.5 Score on a scale STANDARD_DEVIATION 15.3 |
| University of Pennsylvania Smell Identification Test (UPSIT) Score at Baseline | 12.8 Score on a scale STANDARD_DEVIATION 7.9 | 13.3 Score on a scale STANDARD_DEVIATION 7.7 | 13.9 Score on a scale STANDARD_DEVIATION 7.4 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 66 | 0 / 72 |
| other Total, other adverse events | 16 / 66 | 12 / 72 |
| serious Total, serious adverse events | 1 / 66 | 0 / 72 |
Outcome results
Primary
Change From Baseline in Average Daily Nasal Congestion Score (NCS) at Week 24
The Nasal Congestion Score (NCS) was assessed daily by the participant via an electronic diary as the response to the following question: Is your nose blocked? The four available response options were scored from 0 (no symptoms) to 3 (severe symptoms): 0 = Not at all; 1 = Mild; 2 = Moderate; and 3 = Severe. For each study day, a score was calculated using an average of the prior 7 days among the available days within the pre-specified window (For Week 24: Study Days 155 to 186), excluding the study day itself, if a value had been recorded by the participant on at least 4 of the prior 7 days; otherwise, the 7-day prior average for that study day was to be considered missing. One calculated (non-missing) 7-day prior average was selected for analysis according to the study day with nearest proximity to Week 24 (Study Day 168), with the earlier selected in the case of a tie. Baseline was defined as the (non-missing) 7-day interval ending on the latest day prior to randomization.
Time frame: Baseline, Week 24 (Study Days 155 to 186)
Population: Full Analysis Set: all participants randomized to study treatment. Only participants with assessments at Baseline and Week 24 were included in the analysis.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo | Change From Baseline in Average Daily Nasal Congestion Score (NCS) at Week 24 | -0.35 Score on a scale |
| Omalizumab | Change From Baseline in Average Daily Nasal Congestion Score (NCS) at Week 24 | -0.89 Score on a scale |
Comparison: The primary analysis tested the null hypothesis that no treatment group difference existed for change from baseline in NCS at Week 24. As NPS and NCS are co-primary outcome measures, both null hypotheses for NPS and NCS must be rejected, with parameter estimates indicating a benefit of omalizumab over placebo, for the study to be deemed positive.p-value: 0.000495% CI: [-0.84, -0.25]Mixed-Effect Model of Repeated Measures
Primary
Change From Baseline in Nasal Polyp Score (NPS) at Week 24
Total NPS ranges from 0 to 8 (sum of 0-4 for left and right nasal passage scores per the following criteria), with a lower score indicating smaller-sized nasal polyps: 0 = No polyps; 1 = Small polyps in the middle meatus not reaching below the inferior border of the middle turbinate; 2 = Polyps reaching below the lower border of the middle turbinate (modified to accommodate those with a middle turbinectomy, such that polyp must have reached the top of the inferior turbinate.); 3 = Large polyps reaching the lower border of the inferior turbinate or polyps medial to the middle turbinate; and 4 = Large polyps causing complete obstruction of the inferior nasal cavity. Two blinded primary independent expert readers reviewed every post-screening recorded video endoscopy for a given participant to determine total NPS. A third reader chose one of the two scores to be used for analysis in cases where there was any discrepancy in total NPS assigned between the two primary readers.
Time frame: Baseline, Week 24
Population: Full Analysis Set: all participants randomized to study treatment. Only participants with assessments at Baseline and Week 24 were included in the analysis.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo | Change From Baseline in Nasal Polyp Score (NPS) at Week 24 | 0.06 Score on a scale |
| Omalizumab | Change From Baseline in Nasal Polyp Score (NPS) at Week 24 | -1.08 Score on a scale |
Comparison: The primary analysis tested the null hypothesis that no treatment group difference existed for change from baseline in NPS at Week 24. As NPS and NCS are co-primary outcome measures, both null hypotheses for NPS and NCS must be rejected, with parameter estimates indicating a benefit of omalizumab over placebo, for the study to be deemed positive.p-value: <0.000195% CI: [-1.59, -0.69]Mixed-Effect Model of Repeated Measures
Secondary
Change From Baseline in Average Daily Anterior Rhinorrhea Score at Week 24
The Anterior Rhinorrhea Score was assessed daily by the participant via an electronic diary as the response to the following question: Do you have a runny nose? The four available response options were scored from 0 (no symptoms) to 3 (severe symptoms): 0=Not at all; 1=Mild; 2=Moderate; and 3=Severe. For each study day, a score was calculated using an average of the prior 7 days among available days within a pre-specified window (For Week 24: Study Days 155 to 186), excluding the study day itself, if a value had been recorded by the participant on at least 4 of the prior 7 days, otherwise the 7-day prior average for that study day was to be considered missing. One calculated (non-missing) 7-day prior average was selected for analysis according to the study day with nearest proximity to Week 24 (Study Day 168), with the earlier selected in the case of a tie. Baseline was defined as the (non-missing) 7-day interval ending on the latest day prior to randomization.
Time frame: Baseline, Week 24 (Study Days 155 to 186)
Population: Full Analysis Set: all participants randomized to study treatment. Only participants with assessments at Baseline and Week 24 were included in the analysis.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo | Change From Baseline in Average Daily Anterior Rhinorrhea Score at Week 24 | -0.34 Score on a scale |
| Omalizumab | Change From Baseline in Average Daily Anterior Rhinorrhea Score at Week 24 | -0.77 Score on a scale |
Comparison: The null hypothesis was that no difference exists between the treatment groups for change from baseline in the average daily Anterior Rhinorrhea Score (ARS) at Week 24.p-value: 0.002395% CI: [-0.7, -0.16]Mixed-Effect Model of Repeated Measures
Secondary
Change From Baseline in Average Daily Nasal Congestion Score (NCS) at Week 16
The Nasal Congestion Score (NCS) was assessed daily by the participant via an electronic diary as the response to the following question: Is your nose blocked? The four available response options, scored from 0 (no symptoms) to 3 (severe symptoms) were: 0 = Not at all; 1 = Mild; 2 = Moderate; and 3 = Severe. For each study day, a score was calculated using an average of the prior 7 days among the available days within the pre-specified window (For Week 16: Study Days 99 to 126), excluding the study day itself, if a value had been recorded by the participant on at least 4 of the prior 7 days; otherwise, the 7-day prior average for that study day was to be considered missing. One calculated (non-missing) 7-day prior average was selected for analysis according to the study day with nearest proximity to Week 24 (Study Day 112), with the earlier selected in the case of a tie. Baseline was defined as the (non-missing) 7-day interval ending on the latest day prior to randomization.
Time frame: Baseline, Week 16 (Study Days 99 to 126)
Population: Full Analysis Set: all participants randomized to study treatment. Only participants with assessments at Baseline and Week 16 were included in the analysis.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo | Change From Baseline in Average Daily Nasal Congestion Score (NCS) at Week 16 | -0.32 Score on a scale |
| Omalizumab | Change From Baseline in Average Daily Nasal Congestion Score (NCS) at Week 16 | -0.89 Score on a scale |
Comparison: The null hypothesis was that no difference exists between the treatment groups for change from baseline in the average daily NCS at Week 16.p-value: <0.000195% CI: [-0.83, -0.31]Mixed-Effect Model of Repeated Measures
Secondary
Change From Baseline in Average Daily Posterior Rhinorrhea Score at Week 24
The Posterior Rhinorrhea Score was assessed daily by the participant via an electronic diary as the response to the following question: Do you feel dripping at the back of the nose? The four available response options were scored from 0 (no symptoms) to 3 (severe symptoms): 0=Not at all; 1=Mild; 2=Moderate; and 3=Severe. For each study day, a score was calculated using an average of the prior 7 days among available days within a pre-specified window (For Week 24: Study Days 155 to 186), excluding the study day itself, if a value had been recorded by the participant on at least 4 of the prior 7 days, otherwise the 7-day prior average for that study day was to be considered missing. One calculated (non-missing) 7-day prior average was selected for analysis according to the study day with nearest proximity to Week 24 (Study Day 168), with the earlier selected in the case of a tie. Baseline was defined as the (non-missing) 7-day interval ending on the latest day prior to randomization.
Time frame: Baseline, Week 24 (Study Days 155 to 186)
Population: Full Analysis Set: all participants randomized to study treatment. Only participants with assessments at Baseline and Week 24 were included in the analysis.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo | Change From Baseline in Average Daily Posterior Rhinorrhea Score at Week 24 | -0.16 Score on a scale |
| Omalizumab | Change From Baseline in Average Daily Posterior Rhinorrhea Score at Week 24 | -0.72 Score on a scale |
Comparison: The null hypothesis was that no difference exists between the treatment groups for change from baseline in the average daily Posterior Rhinorrhea Score (PRS) at Week 24.p-value: 0.000195% CI: [-0.84, -0.28]Mixed-Effect Model of Repeated Measures
Secondary
Change From Baseline in Average Daily Sense of Smell Score at Week 24
The Sense of Smell Score was assessed daily by the participant via an electronic diary as the response to the following question: Is your sense of smell reduced? The four available response options were scored from 0 (no symptoms) to 3 (severe symptoms): 0 = Not at all; 1 = Mild; 2 = Moderate; and 3 = Severe. For each study day, a score was calculated using an average of the prior 7 days among the available days within the pre-specified window (For Week 24: Study Days 155 to 186), excluding the study day itself, if a value had been recorded by the participant on at least 4 of the prior 7 days; otherwise, the 7-day prior average for that study day was to be considered missing. One calculated (non-missing) 7-day prior average was selected for analysis according to the study day with nearest proximity to Week 24 (Study Day 168), with the earlier selected in the case of a tie. Baseline was defined as the (non-missing) 7-day interval ending on the latest day prior to randomization.
Time frame: Baseline, Week 24 (Study Days 155 to 186)
Population: Full Analysis Set: all participants randomized to study treatment. Only participants with assessments at Baseline and Week 24 were included in the analysis.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo | Change From Baseline in Average Daily Sense of Smell Score at Week 24 | -0.23 Score on a scale |
| Omalizumab | Change From Baseline in Average Daily Sense of Smell Score at Week 24 | -0.56 Score on a scale |
Comparison: The null hypothesis was that no difference exists between the treatment groups for change from baseline in the average daily Sense of Smell Score (SSS) at Week 24.p-value: 0.016195% CI: [-0.6, -0.06]Mixed-Effect Model of Repeated Measures
Secondary
Change From Baseline in Average Daily Total Nasal Symptom Score (TNSS) at Week 24
The Total Nasal Symptom Score (TNSS) was defined as the sum of the four individual scores for Nasal Congestion Score, Anterior Rhinorrhea Score, Posterior Rhinorrhea Score, and Sense of Smell Score, ranging from 0 (no symptoms) to 12 (most severe symptoms), assessed daily by the participant via an electronic diary. For each study day, a score was calculated using an average of the prior 7 days among the available days within the pre-specified window (For Week 24: Study Days 155 to 186), excluding the study day itself, if a value had been recorded by the participant on at least 4 of the prior 7 days; otherwise, the 7-day prior average for that study day was to be considered missing. One calculated (non-missing) 7-day prior average was selected for analysis according to the study day with nearest proximity to Week 24 (Study Day 168), with the earlier selected in the case of a tie. Baseline was defined as the (non-missing) 7-day interval ending on the latest day prior to randomization.
Time frame: Baseline, Week 24 (Study Days 155 to 186)
Population: Full Analysis Set: all participants randomized to study treatment. Only participants with assessments at Baseline and Week 24 were included in the analysis.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo | Change From Baseline in Average Daily Total Nasal Symptom Score (TNSS) at Week 24 | -1.06 Score on a scale |
| Omalizumab | Change From Baseline in Average Daily Total Nasal Symptom Score (TNSS) at Week 24 | -2.97 Score on a scale |
Comparison: The null hypothesis was that no difference exists between the treatment groups for change from baseline in the average daily Total Nasal Symptom Score (TNSS) at Week 24.p-value: 0.000195% CI: [-2.85, -0.96]Mixed-Effect Model of Repeated Measures
Secondary
Change From Baseline in Nasal Polyp Score (NPS) at Week 16
Total NPS ranges from 0 to 8 (sum of 0-4 for left and right nasal passage scores per the following criteria), with a lower score indicating smaller-sized nasal polyps: 0 = No polyps; 1 = Small polyps in the middle meatus not reaching below the inferior border of the middle turbinate; 2 = Polyps reaching below the lower border of the middle turbinate (modified to accommodate those with a middle turbinectomy, such that polyp must have reached the top of the inferior turbinate.); 3 = Large polyps reaching the lower border of the inferior turbinate or polyps medial to the middle turbinate; and 4 = Large polyps causing complete obstruction of the inferior nasal cavity. Two blinded primary independent expert readers reviewed every post-screening recorded video endoscopy for a given participant to determine total NPS. A third reader chose one of the two scores to be used for analysis in cases where there was any discrepancy in total NPS assigned between the two primary readers.
Time frame: Baseline, Week 16
Population: Full Analysis Set: all participants randomized to study treatment. Only participants with assessments at Baseline and Week 16 were included in the analysis.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo | Change From Baseline in Nasal Polyp Score (NPS) at Week 16 | 0.03 Score on a scale |
| Omalizumab | Change From Baseline in Nasal Polyp Score (NPS) at Week 16 | -0.98 Score on a scale |
Comparison: The null hypothesis was that no difference exists between the treatment groups for change from baseline in the NPS at Week 16.p-value: <0.000195% CI: [-1.43, -0.6]Mixed-Effect Model of Repeated Measures
Secondary
Change From Baseline in Participant Reported Health-Related Quality of Life (HRQoL) as Assessed by the Total Sino-Nasal Outcome Test (SNOT)-22 Questionnaire at Week 24
The SNOT-22 Questionnaire, a disease specific HRQoL measure, comprises a list of 22 symptoms and social or emotional consequences of the nasal disorder. Every participant was asked to rate how severe each problem had been for them over the past 2 weeks on a scale from 0 (no problem at all) to 5 (problem as bad as it can be). The total score is the sum of the scores for all 22 items, ranging from 0 to 110, with a lower score indicating less disease and better HRQoL. A negative score indicates a decrease (or improvement) from the baseline score.
Time frame: Baseline, Week 24
Population: Full Analysis Set: all participants randomized to study treatment. Only participants with assessments at Baseline and Week 24 were included in the analysis.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo | Change From Baseline in Participant Reported Health-Related Quality of Life (HRQoL) as Assessed by the Total Sino-Nasal Outcome Test (SNOT)-22 Questionnaire at Week 24 | -8.58 Score on a scale |
| Omalizumab | Change From Baseline in Participant Reported Health-Related Quality of Life (HRQoL) as Assessed by the Total Sino-Nasal Outcome Test (SNOT)-22 Questionnaire at Week 24 | -24.70 Score on a scale |
Comparison: The null hypothesis was that no difference exists between the treatment groups for change from baseline in the SNOT-22 score at Week 24.p-value: <0.000195% CI: [-21.86, -10.38]Mixed-Effect Model of Repeated Measures
Secondary
Change From Baseline in Sense of Smell, as Assessed by The University of Pennsylvania Smell Identification Test (UPSIT) at Week 24
The UPSIT is a 40-question instrument that measures an individual's ability to detect odors and ranges from 0 to 40, with a higher score indicating a better sense of smell. It is a self-administered scratch-and-sniff test provided in booklets that have 40 microencapsulated odorants, each with a multiple-choice option for the response. The number of correct responses is summed to provide a total score.
Time frame: Baseline, Week 24
Population: Full Analysis Set: all participants randomized to study treatment. Only participants with assessments at Baseline and Week 24 were included in the analysis.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo | Change From Baseline in Sense of Smell, as Assessed by The University of Pennsylvania Smell Identification Test (UPSIT) at Week 24 | 0.63 Score on a scale |
| Omalizumab | Change From Baseline in Sense of Smell, as Assessed by The University of Pennsylvania Smell Identification Test (UPSIT) at Week 24 | 4.44 Score on a scale |
Comparison: The null hypothesis was that no difference exists between the treatment groups for change from baseline in the UPSIT score at Week 24.p-value: 0.002495% CI: [1.38, 6.24]Mixed-Effect Model of Repeated Measures
Secondary
Mean Serum Concentration of Omalizumab at Specified Timepoints
Serum concentrations of omalizumab were quantified using an enzyme-linked immunoabsorbent assay (ELISA) with a lower limit of quantification (LLOQ) of 28.0 nanograms per millilitre (ng/mL). According to the analysis plan, values below the lower limit of quantification (BLQ) were set to 14 ng/mL (i.e. half of LLOQ value). If one-third or fewer of participants had results that were BLQ, then all summary statistics were to be calculated. However, if more than one-third of participants had results that were BLQ, then the mean and standard deviation were non-reportable and only the median and maximum were to be calculated for that timepoint.
Time frame: Predose on Day 1, Week 16, Week 24, Unscheduled Visit (outside of planned study visits, as clinically indicated), Dosing Termination/Early Termination Visit (up to 28 weeks)
Population: Pharmacokinetics Evaluable Analysis Set: includes participants who received study drug per protocol. Only the omalizumab-treated participants with evaluable samples at each timepoint were included in this analysis.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Omalizumab | Mean Serum Concentration of Omalizumab at Specified Timepoints | Unscheduled Visit | 6140 nanograms per millilitre (ng/mL) | Standard Deviation 1390 |
| Omalizumab | Mean Serum Concentration of Omalizumab at Specified Timepoints | Day 1 | NA nanograms per millilitre (ng/mL) | — |
| Omalizumab | Mean Serum Concentration of Omalizumab at Specified Timepoints | Week 16 | 29000 nanograms per millilitre (ng/mL) | Standard Deviation 22000 |
| Omalizumab | Mean Serum Concentration of Omalizumab at Specified Timepoints | Week 24 | 31200 nanograms per millilitre (ng/mL) | Standard Deviation 23900 |
| Omalizumab | Mean Serum Concentration of Omalizumab at Specified Timepoints | Dosing Termination/Early Termination Visit | 7490 nanograms per millilitre (ng/mL) | Standard Deviation 4510 |
Secondary
Mean Serum Concentration of Total and Free Immunoglobulin E (IgE) at Specified Timepoints
Serum concentrations of total immunoglobulin E (IgE) and free IgE were measured throughout the 24-week blinded treatment period, as target engagement biomarkers of omalizumab, using validated quantitative immunoassays with lower limits of quantification of 2 and 0.83 International Units per millilitre (IU/mL), respectively, and upper limits of quantification (ULQ) of 5000 and 62.5 IU/mL, respectively. The free IgE assay had limited range to measure circulating levels of free IgE in the presence of complexes of omalizumab-IgE. According to the analysis plan for the free IgE assay, results above ULQ were set to 62.5 IU/mL. If results for one-third or fewer of the participants were greater than the ULQ, then all summary statistics were to be reported. However, if the results for more than one-third of participants were greater than the ULQ, then only the median, interquartile range and minimum were calculated, and the mean, standard deviation, and maximum were non-reportable.
Time frame: Predose on Day 1, Week 16, Week 24
Population: Pharmacokinetics Evaluable Analysis Set: includes participants who received study drug per protocol. The number analyzed includes participants with evaluable samples at each timepoint.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Mean Serum Concentration of Total and Free Immunoglobulin E (IgE) at Specified Timepoints | Total IgE - Day 1 | 187 IU/mL | Standard Deviation 164 |
| Placebo | Mean Serum Concentration of Total and Free Immunoglobulin E (IgE) at Specified Timepoints | Total IgE - Week 16 | 189 IU/mL | Standard Deviation 165 |
| Placebo | Mean Serum Concentration of Total and Free Immunoglobulin E (IgE) at Specified Timepoints | Total IgE - Week 24 | 182 IU/mL | Standard Deviation 164 |
| Placebo | Mean Serum Concentration of Total and Free Immunoglobulin E (IgE) at Specified Timepoints | Free IgE - Day 1 | NA IU/mL | — |
| Placebo | Mean Serum Concentration of Total and Free Immunoglobulin E (IgE) at Specified Timepoints | Free IgE - Week 16 | NA IU/mL | — |
| Placebo | Mean Serum Concentration of Total and Free Immunoglobulin E (IgE) at Specified Timepoints | Free IgE - Week 24 | NA IU/mL | — |
| Omalizumab | Mean Serum Concentration of Total and Free Immunoglobulin E (IgE) at Specified Timepoints | Free IgE - Week 16 | 10.0 IU/mL | Standard Deviation 8.39 |
| Omalizumab | Mean Serum Concentration of Total and Free Immunoglobulin E (IgE) at Specified Timepoints | Total IgE - Day 1 | 168 IU/mL | Standard Deviation 169 |
| Omalizumab | Mean Serum Concentration of Total and Free Immunoglobulin E (IgE) at Specified Timepoints | Free IgE - Day 1 | NA IU/mL | — |
| Omalizumab | Mean Serum Concentration of Total and Free Immunoglobulin E (IgE) at Specified Timepoints | Total IgE - Week 16 | 604 IU/mL | Standard Deviation 368 |
| Omalizumab | Mean Serum Concentration of Total and Free Immunoglobulin E (IgE) at Specified Timepoints | Free IgE - Week 24 | 9.16 IU/mL | Standard Deviation 8.91 |
| Omalizumab | Mean Serum Concentration of Total and Free Immunoglobulin E (IgE) at Specified Timepoints | Total IgE - Week 24 | 594 IU/mL | Standard Deviation 340 |
Secondary
Median Serum Concentration of Omalizumab at Specified Timepoints
Serum concentrations of omalizumab were quantified using an enzyme-linked immunoabsorbent assay (ELISA) with a lower limit of quantification (LLOQ) of 28.0 nanograms per millilitre (ng/mL). According to the analysis plan, values below the lower limit of quantification (BLQ) were set to 14 ng/mL (i.e. half of LLOQ value). If one-third or fewer of participants had results that were BLQ, then all summary statistics were to be calculated. However, if more than one-third of participants had results that were BLQ, then the mean and standard deviation were non-reportable and only the median and maximum were to be calculated for that timepoint.
Time frame: Predose on Day 1, Week 16, Week 24, Unscheduled Visit (outside of planned study visits, as clinically indicated), Dosing Termination/Early Termination Visit (up to 28 weeks)
Population: Pharmacokinetics Evaluable Analysis Set: includes participants who received study drug per protocol. Only the omalizumab-treated participants with evaluable samples at each timepoint were included in this analysis.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Omalizumab | Median Serum Concentration of Omalizumab at Specified Timepoints | Day 1 | 0.00 nanograms per millilitre (ng/mL) |
| Omalizumab | Median Serum Concentration of Omalizumab at Specified Timepoints | Week 16 | 23100 nanograms per millilitre (ng/mL) |
| Omalizumab | Median Serum Concentration of Omalizumab at Specified Timepoints | Week 24 | 24700 nanograms per millilitre (ng/mL) |
| Omalizumab | Median Serum Concentration of Omalizumab at Specified Timepoints | Unscheduled Visit | 6140 nanograms per millilitre (ng/mL) |
| Omalizumab | Median Serum Concentration of Omalizumab at Specified Timepoints | Dosing Termination/Early Termination Visit | 9430 nanograms per millilitre (ng/mL) |
Secondary
Median Serum Concentration of Total and Free Immunoglobulin E (IgE) at Specified Timepoints
Serum concentrations of total immunoglobulin E (IgE) and free IgE were measured throughout the 24-week blinded treatment period, as target engagement biomarkers of omalizumab, using validated quantitative immunoassays with lower limits of quantification of 2 and 0.83 International Units per millilitre (IU/mL), respectively, and upper limits of quantification (ULQ) of 5000 and 62.5 IU/mL, respectively. The free IgE assay had limited range to measure circulating levels of free IgE in the presence of complexes of omalizumab-IgE. According to the analysis plan for the free IgE assay, results above ULQ were set to 62.5 IU/mL. If results for one-third or fewer of the participants were greater than the ULQ, then all summary statistics were to be reported. However, if the results for more than one-third of participants were greater than the ULQ, then only the median, interquartile range and minimum were calculated, and the mean, standard deviation, and maximum were non-reportable.
Time frame: Predose on Day 1, Week 16, Week 24
Population: Pharmacokinetics Evaluable Analysis Set: includes participants who received study drug per protocol. The number analyzed includes participants with evaluable samples at each timepoint.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Placebo | Median Serum Concentration of Total and Free Immunoglobulin E (IgE) at Specified Timepoints | Total IgE - Day 1 | 165 IU/mL |
| Placebo | Median Serum Concentration of Total and Free Immunoglobulin E (IgE) at Specified Timepoints | Total IgE - Week 16 | 138 IU/mL |
| Placebo | Median Serum Concentration of Total and Free Immunoglobulin E (IgE) at Specified Timepoints | Total IgE - Week 24 | 143 IU/mL |
| Placebo | Median Serum Concentration of Total and Free Immunoglobulin E (IgE) at Specified Timepoints | Free IgE - Day 1 | 62.5 IU/mL |
| Placebo | Median Serum Concentration of Total and Free Immunoglobulin E (IgE) at Specified Timepoints | Free IgE - Week 16 | 62.5 IU/mL |
| Placebo | Median Serum Concentration of Total and Free Immunoglobulin E (IgE) at Specified Timepoints | Free IgE - Week 24 | 62.5 IU/mL |
| Omalizumab | Median Serum Concentration of Total and Free Immunoglobulin E (IgE) at Specified Timepoints | Free IgE - Week 16 | 7.85 IU/mL |
| Omalizumab | Median Serum Concentration of Total and Free Immunoglobulin E (IgE) at Specified Timepoints | Total IgE - Day 1 | 121 IU/mL |
| Omalizumab | Median Serum Concentration of Total and Free Immunoglobulin E (IgE) at Specified Timepoints | Free IgE - Day 1 | 62.5 IU/mL |
| Omalizumab | Median Serum Concentration of Total and Free Immunoglobulin E (IgE) at Specified Timepoints | Total IgE - Week 16 | 505 IU/mL |
| Omalizumab | Median Serum Concentration of Total and Free Immunoglobulin E (IgE) at Specified Timepoints | Free IgE - Week 24 | 7.02 IU/mL |
| Omalizumab | Median Serum Concentration of Total and Free Immunoglobulin E (IgE) at Specified Timepoints | Total IgE - Week 24 | 498 IU/mL |
Secondary
Number of Participants Having Had Surgery for Nasal Polyps Through Week 24
A participant was considered to have had the event of surgery for nasal polyps if they underwent the procedure at any point between randomization and Week 24; if the participant had greater than 155 days of follow-up on study and had not undergone surgery for nasal polyps, then they did not have the event. Participants with less than 155 days of follow-up on the study were classified as having had the event if they discontinued study drug due to adverse event, progressive disease, or lack of efficacy and remained missing; if the participant had less than 155 days of follow-up on study and had not already met these criteria, they were classified as having a missing outcome. The null hypothesis was to be assessed by the Wald Chi-square test of the treatment term in the logistic regression model. If model convergence was an issue, then Fisher's Exact test was to be used.
Time frame: Up to Week 24
Population: Full Analysis Set: all participants randomized to study treatment. Only participants on study through Week 24 were included in the analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants Having Had Surgery for Nasal Polyps Through Week 24 | 1 Participants |
| Omalizumab | Number of Participants Having Had Surgery for Nasal Polyps Through Week 24 | 0 Participants |
Comparison: The null hypothesis was that no difference exists between the treatment groups for having had surgery for nasal polyps through Week 24.p-value: 0.481595% CI: [0, 17.64]Fisher Exact
Secondary
Number of Participants Requiring Rescue Medication (Systemic Corticosteroids for ≥3 Consecutive Days) Through Week 24
A participant was considered to have had the event of requiring rescue medication if they had taken systemic corticosteroids for 3 or more consecutive days at any point between randomization and Week 24; if the participant had greater than 155 days of follow-up on study and had not taken systemic corticosteroids for 3 or more consecutive days, then they did not have the event. Participants with less than 155 days of follow-up on the study were classified as having had the event if they discontinued study drug due to adverse event, progressive disease, or lack of efficacy and remained missing; if the participant had less than 155 days of follow-up on study and had not already met these criteria, they were classified as having a missing outcome. The null hypothesis was to be assessed by the Wald Chi-square test of the treatment term in the logistic regression model. If model convergence was an issue, then Fisher's Exact test was to be used.
Time frame: Up to Week 24
Population: Full Analysis Set: all participants randomized to study treatment. Only participants on study through Week 24 were included in the analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants Requiring Rescue Medication (Systemic Corticosteroids for ≥3 Consecutive Days) Through Week 24 | 3 Participants |
| Omalizumab | Number of Participants Requiring Rescue Medication (Systemic Corticosteroids for ≥3 Consecutive Days) Through Week 24 | 2 Participants |
Comparison: The null hypothesis was that no difference exists between the treatment groups for requirement of rescue medication through Week 24.p-value: 0.671695% CI: [0.05, 5.51]Fisher Exact
Secondary
Number of Participants Requiring Rescue Treatment (Systemic Corticosteroids For ≥3 Consecutive Days or Having Had Surgery for Nasal Polyps) Through Week 24
A participant was considered to have had the event of requiring rescue treatment if they had taken systemic corticosteroids for 3 or more consecutive days or had nasal polypectomy at any point between randomization and Week 24; if the participant had greater than 155 days of follow-up on study and had not received rescue treatment, then they did not have the event. Participants with less than 155 days of follow-up on the study were classified as having had the event if they discontinued study drug due to adverse event, progressive disease, or lack of efficacy and remained missing; if the participant had less than 155 days of follow-up on study and had not already met these criteria, they were classified as having a missing outcome. The null hypothesis was to be assessed by the Wald Chi-square test of the treatment term in the logistic regression model. If model convergence was an issue, then Fisher's Exact test was to be used.
Time frame: Up to Week 24
Population: Full Analysis Set: all participants randomized to study treatment. Only participants on study through Week 24 were included in the analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants Requiring Rescue Treatment (Systemic Corticosteroids For ≥3 Consecutive Days or Having Had Surgery for Nasal Polyps) Through Week 24 | 3 Participants |
| Omalizumab | Number of Participants Requiring Rescue Treatment (Systemic Corticosteroids For ≥3 Consecutive Days or Having Had Surgery for Nasal Polyps) Through Week 24 | 2 Participants |
Comparison: The null hypothesis was that no difference exists between the treatment groups for requirement of rescue treatment through Week 24.p-value: 0.671695% CI: [0.05, 5.51]Fisher Exact
Secondary
Number of Participants Who Experienced at Least One Adverse Event by Greatest Severity
All adverse events (AE) were treatment emergent AEs, defined as any new AE or any worsening of an existing condition with an onset date on or after the first study drug administration date. AEs were assessed for severity according to the following grading scale: mild (discomfort noticed, but no disruption of normal daily activity), moderate (discomfort sufficient to reduce or affect normal daily activity), or severe (incapacitating with inability to work or to perform normal daily activity). The terms severe and serious are not synonymous; regardless of severity, some events may have also met seriousness criteria. Multiple occurrences of the same AE in one individual are counted once at the greatest intensity.
Time frame: Up to Week 28
Population: Safety Analysis Set: all participants who received at least one dose of study drug, grouped according to treatment received during the treatment period.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Placebo | Number of Participants Who Experienced at Least One Adverse Event by Greatest Severity | AEs of Any Severity | 41 Participants |
| Placebo | Number of Participants Who Experienced at Least One Adverse Event by Greatest Severity | Mild AEs | 20 Participants |
| Placebo | Number of Participants Who Experienced at Least One Adverse Event by Greatest Severity | Moderate AEs | 18 Participants |
| Placebo | Number of Participants Who Experienced at Least One Adverse Event by Greatest Severity | Severe AEs | 3 Participants |
| Omalizumab | Number of Participants Who Experienced at Least One Adverse Event by Greatest Severity | Severe AEs | 1 Participants |
| Omalizumab | Number of Participants Who Experienced at Least One Adverse Event by Greatest Severity | AEs of Any Severity | 36 Participants |
| Omalizumab | Number of Participants Who Experienced at Least One Adverse Event by Greatest Severity | Moderate AEs | 20 Participants |
| Omalizumab | Number of Participants Who Experienced at Least One Adverse Event by Greatest Severity | Mild AEs | 15 Participants |
Secondary
Number of Participants Who Experienced at Least One Serious Adverse Event
A serious adverse event was defined as any adverse event that met any of the following criteria: was fatal; was life-threatening; required or prolonged inpatient hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the study drug; or, was a significant medical event in the investigator's judgment. Multiple occurrences of the same serious adverse event in one individual were counted once.
Time frame: Up to Week 28
Population: Safety Analysis Set: all participants who received at least one dose of study drug, grouped according to treatment received during the treatment period.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants Who Experienced at Least One Serious Adverse Event | 1 Participants |
| Omalizumab | Number of Participants Who Experienced at Least One Serious Adverse Event | 0 Participants |
Secondary
Number of Participants With a Change From Baseline at Week 24 in Asthma Quality of Life Questionnaire (AQLQ) of ≥0.5 in Participants With Comorbid Asthma Only
The AQLQ is a 32-item participant-reported measure of asthma-related quality of life (QoL) with a total score (the mean of all 32 responses) ranging from 1 (severely impaired) to 7 (not impaired at all); a higher score indicates a better QoL. An increase of at least 0.5 points in the AQLQ score was considered the minimal important difference for improvement in QoL.
Time frame: Baseline, Week 24
Population: Analysis was conducted only in the subgroup of participants with comorbid asthma at screening and AQLQ assessments at Baseline and Week 24.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants With a Change From Baseline at Week 24 in Asthma Quality of Life Questionnaire (AQLQ) of ≥0.5 in Participants With Comorbid Asthma Only | 9 Participants |
| Omalizumab | Number of Participants With a Change From Baseline at Week 24 in Asthma Quality of Life Questionnaire (AQLQ) of ≥0.5 in Participants With Comorbid Asthma Only | 20 Participants |
Comparison: The null hypothesis was that no difference exists between the treatment groups for number of participants with a change from baseline in AQLQ score of ≥0.5 at Week 24.p-value: 0.049295% CI: [1, 13.71]Wald Chi-Square
Secondary
Number of Participants With Adverse Events Leading to Omalizumab/Placebo Discontinuation
Time frame: Up to Week 24
Population: Safety Analysis Set: all participants who received at least one dose of study drug, grouped according to treatment received during the treatment period.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants With Adverse Events Leading to Omalizumab/Placebo Discontinuation | 1 Participants |
| Omalizumab | Number of Participants With Adverse Events Leading to Omalizumab/Placebo Discontinuation | 0 Participants |
Secondary
Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline
Clinical laboratory tests for serum chemistry and hematology parameters were performed at laboratories; any abnormal values (High or Low) were based on laboratory normal ranges. Laboratory abnormalities are presented by the highest grade according to the World Health Organization (WHO) grade for Adverse Events, except for eosinophils and white blood cells that were graded according to the FDA Toxicity Grading Scale for Healthy Volunteers. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. SGPT/ALT = serum glutamic-pyruvic transaminase/alanine aminotransferase; SGOT/AST = serum glutamic-oxaloacetic transaminase/aspartate aminotransferase
Time frame: Up to Week 28
Population: Safety Analysis Set: all participants who received at least one dose of study drug, grouped according to treatment received during the treatment period.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Total Leukocyte Count - High, Gr. 1 | 4 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Neutrophils, Segmented (Abs.) - Low, Gr. 1 | 5 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Alkaline Phosphatase - High, Any Grade (Gr.) | 0 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Sodium - High, Gr. 1 | 4 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Alkaline Phosphatase - High, Gr. 1 | 0 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Potassium - High, Any Gr. | 3 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | SGPT/ALT - High, Any Gr. | 5 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Bilirubin - High, Any Gr. | 1 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | SGPT/ALT - High, Gr. 1 | 5 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Platelet - Low, Any Gr. | 0 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | SGPT/ALT - High, Gr. 3 | 0 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Bilirubin - High, Gr. 1 | 1 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | SGOT/AST - High, Any Gr. | 1 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Potassium - High, Gr. 1 | 3 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | SGOT/AST - High, Gr. 1 | 1 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Bilirubin - High, Gr. 2 | 0 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | SGOT/AST - High, Gr. 2 | 0 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Neutrophils, Segmented (Abs.) - Low, Gr. 2 | 3 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Creatinine - High, Any Gr. | 0 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Total Leukocyte Count - Low, Any Gr. | 4 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Eosinophils, Absolute Count (Abs.) - High, Any Gr. | 12 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Sodium - Low, Any Gr. | 0 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Eosinophils, Abs. - High, Gr. 1 | 12 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Total Leukocyte Count - Low, Gr. 1 | 4 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Eosinophils, Abs. - High, Gr. 2 | 0 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Potassium - Low, Any Gr. | 0 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Hemoglobin - Low, Any Gr. | 0 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Total Leukocyte Count - High, Any Gr. | 4 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Hemoglobin - High, Any Gr. | 0 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Sodium - High, Any Gr. | 4 Participants |
| Placebo | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Neutrophils, Segmented (Abs.) - Low, Any Gr. | 8 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | SGPT/ALT - High, Any Gr. | 4 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Neutrophils, Segmented (Abs.) - Low, Gr. 1 | 3 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Neutrophils, Segmented (Abs.) - Low, Gr. 2 | 1 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Platelet - Low, Any Gr. | 0 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Potassium - Low, Any Gr. | 0 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Potassium - High, Any Gr. | 0 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Potassium - High, Gr. 1 | 0 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Sodium - Low, Any Gr. | 0 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Sodium - High, Any Gr. | 2 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Sodium - High, Gr. 1 | 2 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Bilirubin - High, Any Gr. | 3 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Bilirubin - High, Gr. 1 | 1 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Bilirubin - High, Gr. 2 | 2 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Total Leukocyte Count - Low, Any Gr. | 1 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Total Leukocyte Count - Low, Gr. 1 | 1 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Total Leukocyte Count - High, Any Gr. | 3 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Total Leukocyte Count - High, Gr. 1 | 3 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Alkaline Phosphatase - High, Any Grade (Gr.) | 2 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Alkaline Phosphatase - High, Gr. 1 | 2 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Neutrophils, Segmented (Abs.) - Low, Any Gr. | 4 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | SGPT/ALT - High, Gr. 1 | 3 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | SGPT/ALT - High, Gr. 3 | 1 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | SGOT/AST - High, Any Gr. | 2 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | SGOT/AST - High, Gr. 1 | 0 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | SGOT/AST - High, Gr. 2 | 2 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Creatinine - High, Any Gr. | 0 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Eosinophils, Absolute Count (Abs.) - High, Any Gr. | 8 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Eosinophils, Abs. - High, Gr. 1 | 7 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Eosinophils, Abs. - High, Gr. 2 | 1 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Hemoglobin - Low, Any Gr. | 0 Participants |
| Omalizumab | Number of Participants With Laboratory Abnormalities by Highest Grade Post-Baseline | Hemoglobin - High, Any Gr. | 0 Participants |
Secondary
Number of Participants With Reduction in the Need for Surgery for Nasal Polyps by Week 24, as Defined by an NPS of ≤4 (Unilateral Score of ≤2 on Each Side) and Improvement in SNOT-22 Score of ≥8.9
A participant was considered to have had the event of reduction in the need for surgery for nasal polyps if they had a Nasal Polyp Score (NPS) of ≤4 and an improvement in the SNOT-22 score of ≥8.9 (minimal important difference) without rescue treatment at Week 24; if the participant had received rescue treatment or had discontinued study drug due to adverse event, progressive disease, or lack of efficacy and remained missing, then they did not have the event. Participants without an intercurrent event and without valid Week 24 assessments of both NPS and SNOT-22 were classified as having a missing outcome. The null hypothesis was to be assessed by the Wald Chi-square test of the treatment term in the logistic regression model. If model convergence was an issue, then Fisher's Exact test was to be used.
Time frame: Up to Week 24
Population: Full Analysis Set: all participants randomized to study treatment. Only participants with assessments at Baseline and Week 24 were included in the analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants With Reduction in the Need for Surgery for Nasal Polyps by Week 24, as Defined by an NPS of ≤4 (Unilateral Score of ≤2 on Each Side) and Improvement in SNOT-22 Score of ≥8.9 | 2 Participants |
| Omalizumab | Number of Participants With Reduction in the Need for Surgery for Nasal Polyps by Week 24, as Defined by an NPS of ≤4 (Unilateral Score of ≤2 on Each Side) and Improvement in SNOT-22 Score of ≥8.9 | 13 Participants |
Comparison: The null hypothesis was that no difference exists between the treatment groups for change from baseline in reduction in the need for surgery for nasal polyps by Week 24.p-value: 0.020995% CI: [1.32, 29.6]Wald Chi-Square